Jane Street Group LLC Invests $265,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Jane Street Group LLC bought a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 50,221 shares of the company’s stock, valued at approximately $265,000.

Several other institutional investors have also recently made changes to their positions in the business. Samlyn Capital LLC grew its position in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $10,855,000. State Street Corp grew its position in shares of Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after purchasing an additional 53,809 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $136,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CRVS shares. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Oppenheimer raised their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright assumed coverage on Corvus Pharmaceuticals in a report on Thursday, January 2nd. They set a “buy” rating and a $11.00 price target for the company. Finally, LADENBURG THALM/SH SH raised their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a report on Monday, September 16th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Price Performance

NASDAQ CRVS opened at $5.33 on Friday. The stock has a market capitalization of $342.49 million, a PE ratio of -5.73 and a beta of 1.07. The business has a 50 day simple moving average of $7.36 and a two-hundred day simple moving average of $5.42. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.